Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.

Sander S, Calado DP, Srinivasan L, Köchert K, Zhang B, Rosolowski M, Rodig SJ, Holzmann K, Stilgenbauer S, Siebert R, Bullinger L, Rajewsky K.

Cancer Cell. 2012 Aug 14;22(2):167-79. doi: 10.1016/j.ccr.2012.06.012.

2.

Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells.

Sander S, Rajewsky K.

Oncotarget. 2012 Oct;3(10):1066-7. No abstract available.

3.

Burkitt lymphoma: much more than MYC.

Dominguez-Sola D, Dalla-Favera R.

Cancer Cell. 2012 Aug 14;22(2):141-2. doi: 10.1016/j.ccr.2012.07.018.

4.

Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.

Spender LC, Inman GJ.

Mol Cancer Res. 2012 Mar;10(3):347-59. doi: 10.1158/1541-7786.MCR-11-0394. Epub 2012 Jan 12.

5.

Myc suppression of Nfkb2 accelerates lymphomagenesis.

Keller U, Huber J, Nilsson JA, Fallahi M, Hall MA, Peschel C, Cleveland JL.

BMC Cancer. 2010 Jul 2;10:348. doi: 10.1186/1471-2407-10-348.

6.

c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma.

Scheller H, Tobollik S, Kutzera A, Eder M, Unterlehberg J, Pfeil I, Jungnickel B.

Oncogene. 2010 Feb 11;29(6):888-97. doi: 10.1038/onc.2009.377. Epub 2009 Nov 2.

PMID:
19881537
7.

Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis.

Garrison SP, Jeffers JR, Yang C, Nilsson JA, Hall MA, Rehg JE, Yue W, Yu J, Zhang L, Onciu M, Sample JT, Cleveland JL, Zambetti GP.

Mol Cell Biol. 2008 Sep;28(17):5391-402. doi: 10.1128/MCB.00907-07. Epub 2008 Jun 23.

8.

NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.

Han SS, Yun H, Son DJ, Tompkins VS, Peng L, Chung ST, Kim JS, Park ES, Janz S.

Mol Cancer. 2010 Apr 30;9:97. doi: 10.1186/1476-4598-9-97.

9.

MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas.

Schneider C, Setty M, Holmes AB, Maute RL, Leslie CS, Mussolin L, Rosolen A, Dalla-Favera R, Basso K.

Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8185-90. doi: 10.1073/pnas.1322466111. Epub 2014 May 19.

10.

The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis.

Klapproth K, Sander S, Marinkovic D, Baumann B, Wirth T.

Blood. 2009 Sep 17;114(12):2448-58. doi: 10.1182/blood-2008-09-181008. Epub 2009 Jul 23.

11.

Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis.

Maclean KH, Dorsey FC, Cleveland JL, Kastan MB.

J Clin Invest. 2008 Jan;118(1):79-88. Erratum in: J Clin Invest. 2008 Apr;118(4):1584.

12.

Forward and reverse changes in Ig/myc translocation carrying tumors.

Klein G.

Princess Takamatsu Symp. 1989;20:135-42.

PMID:
2562178
13.

Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells.

Zhu D, Qi CF, Morse HC 3rd, Janz S, Stevenson FK.

Blood. 2005 Mar 1;105(5):2135-7. Epub 2004 Nov 2.

14.

The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.

Rodig SJ, Kutok JL, Paterson JC, Nitta H, Zhang W, Chapuy B, Tumwine LK, Montes-Moreno S, Agostinelli C, Johnson NA, Ben-Neriah S, Farinha P, Shipp MA, Piris MA, Grogan TM, Pileri SA, Gascoyne RD, Marafioti T.

Haematologica. 2010 Dec;95(12):2056-62. doi: 10.3324/haematol.2010.025767. Epub 2010 Sep 7.

16.

Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.

Ferreira AC, Robaina MC, Rezende LM, Severino P, Klumb CE.

Ann Hematol. 2014 Jun;93(6):983-93. doi: 10.1007/s00277-014-2021-4. Epub 2014 Feb 28.

PMID:
24577510
17.

Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.

Ferreira AC, de-Freitas-Junior JC, Morgado-Díaz JA, Ridley AJ, Klumb CE.

J Leukoc Biol. 2016 Apr;99(4):569-78. doi: 10.1189/jlb.2A0415-162R. Epub 2015 Nov 11.

PMID:
26561567
18.

Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma.

Yoon JW, Gallant M, Lamm ML, Iannaccone S, Vieux KF, Proytcheva M, Hyjek E, Iannaccone P, Walterhouse D.

Mol Cancer Res. 2013 Jun;11(6):604-15. doi: 10.1158/1541-7786.MCR-12-0441. Epub 2013 Mar 22.

19.

The 3' IgH locus control region is sufficient to deregulate a c-myc transgene and promote mature B cell malignancies with a predominant Burkitt-like phenotype.

Truffinet V, Pinaud E, Cogné N, Petit B, Guglielmi L, Cogné M, Denizot Y.

J Immunol. 2007 Nov 1;179(9):6033-42.

20.

Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.

Vettraino M, Manerba M, Govoni M, Di Stefano G.

Anticancer Drugs. 2013 Sep;24(8):862-70. doi: 10.1097/CAD.0b013e328363ae50.

PMID:
23797802
Items per page

Supplemental Content

Write to the Help Desk